Showing results (2001-2010 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|September 1, 2005
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancersHedy L Kindler, Peter K Tothy, Robert Wolff, et al.Investigational New Drugs|April 4, 2006
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancerMilin R Acharya, Judith E Karp, Edward A Sausville, et al.Investigational New Drugs|May 16, 2006
Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinomaC Bolling, T Graefe, C Lübbing, et al.Investigational New Drugs|February 1, 1990
Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analogR A Newman, Z H Siddik, E L Travis, et al.Investigational New Drugs|January 1, 1990
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancerA Mittelman, S Savona, C Puccio, et al.Investigational New Drugs|May 1, 1990
Phase II trial of carboplatin in patients with advanced melanomaE S Casper, D BajorinInvestigational New Drugs|April 7, 2006
Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in ratsKumaraswami Deeptha, Muthaiyan Kamaleeswari, Murugan Sengottuvelan, et al.Investigational New Drugs|February 28, 2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaElisabeth I Heath, Barbara A Burtness, Lawrence Kleinberg, et al.Investigational New Drugs|February 28, 2006
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patientsJing Li, Julie Brahmer, Wells Messersmith, et al.Pageof 372